Published in Circulation on June 07, 2004
WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW - ACS) (WILLOW ACS) | NCT02741817
Does Mean Platelet Volume Change With Clopidogrel | NCT02550301
Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis. BMJ (2014) 2.21
The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther (2007) 2.18
Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ (2006) 2.01
Personalized medicine: hope or hype? Eur Heart J (2012) 1.80
Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. Circulation (2009) 1.77
Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther (2009) 1.73
Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov (2010) 1.66
Endovascular occlusion of intracranial wide-necked aneurysms with stenting (Neuroform) and coiling: mid-term and long-term results. Neuroradiology (2009) 1.49
Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects. Eur J Clin Pharmacol (2010) 1.13
Platelet function in patients with diabetes mellitus: from a theoretical to a practical perspective. Int J Endocrinol (2011) 1.12
Clopidogrel resistance: a new chapter in a fast-moving story. Circulation (2004) 1.08
Interaction between cigarette smoking and clinical benefit of clopidogrel. J Am Coll Cardiol (2009) 1.07
Historical perspective and future directions in platelet research. J Thromb Haemost (2011) 1.06
Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. Br J Clin Pharmacol (2010) 1.06
Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine. Am J Drug Alcohol Abuse (2009) 1.02
Adoption of prasugrel into routine practice: rationale and design of the Rijnmond Collective Cardiology Research (CCR) study in percutaneous coronary intervention for acute coronary syndromes. Neth Heart J (2014) 1.00
Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J (2008) 0.99
The significance of clopidogrel low-responsiveness on stent thrombosis and cardiac death assessed by the verifynow p(2)y(12) assay in patients with acute coronary syndrome within 6 months after drug-eluting stent implantation. Korean Circ J (2009) 0.99
Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements. Nat Rev Cardiol (2009) 0.97
A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans. Br J Clin Pharmacol (2006) 0.96
Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention. J Am Soc Nephrol (2011) 0.96
Genetic determinants of platelet response to clopidogrel. J Thromb Thrombolysis (2011) 0.96
Clinical importance of aspirin and clopidogrel resistance. World J Cardiol (2010) 0.95
ABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: a meta-analysis. PLoS One (2012) 0.91
High residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistance. Cardiovasc Diagn Ther (2013) 0.91
Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy. PLoS One (2013) 0.91
Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting. Vasc Health Risk Manag (2009) 0.90
Current concepts on antiplatelet therapy: focus on the novel thienopyridine and non-thienopyridine agents. Adv Hematol (2010) 0.89
Oral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options. Vasc Health Risk Manag (2012) 0.88
Is platelet inhibition due to thienopyridines increased in elderly patients, in patients with previous stroke and patients with low body weight as a possible explanation of an increased bleeding risk? Neth Heart J (2011) 0.87
The impact of generic clopidogrel bisulfate on platelet inhibition in patients with coronary artery stents: results of the ACCEL-GENERIC study. Korean J Intern Med (2010) 0.87
Determinants to optimize response to clopidogrel in acute coronary syndrome. Pharmgenomics Pers Med (2010) 0.87
Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions? Br J Clin Pharmacol (2011) 0.87
Biological basis and clinical implications of acetylsalicylic acid resistance. Can J Cardiol (2006) 0.87
Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel. Coron Artery Dis (2009) 0.86
Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome. Vasc Health Risk Manag (2010) 0.85
Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls. Postepy Kardiol Interwencyjnej (2015) 0.84
Aspirin and clopidogrel response variability: review of the published literature. Tex Heart Inst J (2008) 0.84
Antiplatelet therapy in populations at high risk of atherothrombosis. J Natl Med Assoc (2006) 0.84
High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study. JACC Cardiovasc Imaging (2012) 0.83
Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation? J Hum Genet (2013) 0.83
Recent advances in the pharmacogenetics of clopidogrel. Hum Genet (2011) 0.83
Effects of cilostazol on platelet activation in coronary stenting patients who already treated with aspirin and clopidogrel. Korean J Intern Med (2004) 0.83
[13C]pantoprazole breath test as a predictor of the anti-platelet function of clopidogrel. Eur J Clin Pharmacol (2010) 0.83
A randomized study assessing the effects of pretreatment with cilostazol on periprocedural myonecrosis after percutaneous coronary intervention. Yonsei Med J (2011) 0.82
Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease. PLoS One (2014) 0.82
Oncocalyxone A inhibits human platelet aggregation by increasing cGMP and by binding to GP Ibalpha glycoprotein. Br J Pharmacol (2008) 0.82
Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Vasc Health Risk Manag (2009) 0.81
The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel. Thromb J (2011) 0.81
Pharmacogenomics of anti-platelet and anti-coagulation therapy. Curr Cardiol Rep (2013) 0.81
Significance of clopidogrel resistance related to the stent-assisted angioplasty in patients with atherosclerotic cerebrovascular disease. J Korean Neurosurg Soc (2011) 0.81
Point-of-care platelet function testing in patients undergoing PCI: between a rock and a hard place. Neth Heart J (2007) 0.81
Residual platelet ADP reactivity after clopidogrel treatment is dependent on activation of both the unblocked P2Y(1) and the P2Y (12) receptor and is correlated with protein expression of P2Y (12). Purinergic Signal (2006) 0.81
Frequency of CYP3A4, CYP3A5, CYP2C9, and CYP2C19 variant alleles in patients receiving clopidogrel that experience repeat acute coronary syndrome. Heart Vessels (2009) 0.81
Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update. Clin Pharmacokinet (2015) 0.80
Antiplatelet treatment for coronary heart disease. Heart (2007) 0.80
The impact of smoking on post-clopidogrel platelet reactivity in patients with acute myocardial infarction. Korean Circ J (2010) 0.80
Eptifibatide: The evidence for its role in the management of acute coronary syndromes. Core Evid (2010) 0.80
Use of native or platelet count adjusted platelet rich plasma for platelet aggregation measurements. J Clin Pathol (2005) 0.80
Clopidogrel resistance is associated with long-term thrombotic events in patients implanted with drug-eluting stents. Drugs R D (2010) 0.79
Evolving role of platelet function testing in coronary artery interventions. Vasc Health Risk Manag (2012) 0.79
Impact of dual antiplatelet therapy with proton pump inhibitors on the outcome of patients with acute coronary syndrome undergoing drug-eluting stent implantation. ISRN Cardiol (2012) 0.79
Antiplatelet therapy for carotid artery stenting. Interv Neurol (2013) 0.79
Association of P2Y12 gene promoter DNA methylation with the risk of clopidogrel resistance in coronary artery disease patients. Biomed Res Int (2014) 0.79
Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study. Postgrad Med J (2006) 0.79
P2Y12 Receptor Inhibitors in Acute Coronary Syndromes: What Is New on the Horizon? Cardiol Res Pract (2013) 0.79
Bleeding tendency in dual antiplatelet therapy with aspirin/clopidogrel: rescue of the template bleeding time in a single-center prospective study. Thromb J (2012) 0.79
Thrombostatin FM compounds: direct thrombin inhibitors - mechanism of action in vitro and in vivo. J Thromb Haemost (2008) 0.79
Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention. Eur J Clin Pharmacol (2012) 0.79
Current status of high on-treatment platelet reactivity in patients with coronary or peripheral arterial disease: Mechanisms, evaluation and clinical implications. World J Cardiol (2015) 0.79
Detection of clopidogrel hyporesponsiveness using a point-of-care assay and the impact of additional cilostazol administration after coronary stent implantation in diabetic patients. Korean J Intern Med (2011) 0.78
Routine screening for CYP2C19 polymorphisms for patients being treated with clopidogrel is not recommended. Hawaii J Med Public Health (2015) 0.78
Proton pump inhibitors and clopidogrel - hazardous drug interaction or hazardous interpretation of data? Can J Gastroenterol (2009) 0.78
Effects of Clopidogrel and Proton Pump Inhibitors on Cardiovascular Events in Patients with Type 2 Diabetes Mellitus after Drug-Eluting Stent Implantation: A Nationwide Cohort Study. PLoS One (2015) 0.78
Gene polymorphism of cytochrome P450 2C19*2 and clopidogrel resistance reflected by platelet function assays: a meta-analysis. Eur J Clin Pharmacol (2014) 0.78
Stent thrombosis associated with first-generation drug-eluting stents: issues with antiplatelet therapy. Neth Heart J (2007) 0.78
Intracranial stenting for severe symptomatic stenosis: self-expandable versus balloon-expandable stents. Interv Neuroradiol (2013) 0.78
The influence of anti-platelet resistance on the development of cerebral ischemic lesion after carotid artery stenting. Yonsei Med J (2013) 0.78
Von Willebrand factor antigen predicts response to double dose of aspirin and clopidogrel by PFA-100 in patients undergoing primary angioplasty for ST elevation myocardial infarction. ScientificWorldJournal (2013) 0.78
The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics. Cardiol Res Pract (2017) 0.78
Antiplatelet Resistance-Does it Exist and How to Measure it? Clin Med Cardiol (2009) 0.78
The risk of clopidogrel resistance is associated with ABCB1 polymorphisms but not promoter methylation in a Chinese Han population. PLoS One (2017) 0.77
Clopidogrel resistance: the way forward. Indian Heart J (2014) 0.77
A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among patients with ST-elevation myocardial infarction: the RAPID STEMI study. Pharmacogenomics J (2015) 0.77
Resistance to Clopidogrel among Iranian Patients Undergoing Angioplasty Intervention. Iran J Pharm Res (2013) 0.77
The interaction between clopidogrel and proton pump inhibitors (PPI): is there any clinical relevance? Clin Pharmacol (2010) 0.77
TRITON and beyond: new insights into the profile of prasugrel. Cardiovasc Ther (2011) 0.77
Use of a thrombelastograph platelet mapping assay for diagnosis of clopidogrel resistance: a case report. J Extra Corpor Technol (2009) 0.77
Ticagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial. Sci Rep (2015) 0.77
Non ST segment elevation acute coronary syndromes: A simplified risk-orientated algorithm. Can J Cardiol (2006) 0.76
Comparing of light transmittance aggregometry and modified thrombelastograph in predicting clinical outcomes in Chinese patients undergoing coronary stenting with clopidogrel. Chin Med J (Engl) (2015) 0.76
The variability of platelet response to aspirin and clopidogrel: revisiting the Caprie, Cure, Credo, and Match trials. Proc (Bayl Univ Med Cent) (2005) 0.76
Comparing the antiplatelet effect of clopidogrel hydrogensulfate and clopidogrel besylate: a crossover study. Clin Res Cardiol (2009) 0.76
A pharmacodynamic comparison of 5 anti-platelet protocols in patients with ST-elevation myocardial infarction undergoing primary PCI. BMC Cardiovasc Disord (2014) 0.76
Combined aspirin and clopidogrel resistance associated with recurrent coronary stent thrombosis. Clin Res Cardiol (2006) 0.76
Simultaneous multi-vessel subacute stent thromboses in zotarolimus-eluting stents. Korean Circ J (2010) 0.75
Smoking Interaction with Clopidogrel; Another Smoker's Paradox? Korean Circ J (2010) 0.75
Dual antiplatelet therapy in secondary prevention of ischemic stroke: a ghost from the past or a new frontier? Stroke Res Treat (2010) 0.75
Universal definition of myocardial infarction. Circulation (2007) 11.69
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
Third universal definition of myocardial infarction. Circulation (2012) 8.47
Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98
Transcatheter aortic valve replacement for degenerative bioprosthetic surgical valves: results from the global valve-in-valve registry. Circulation (2012) 3.30
Long QT syndrome in adults. J Am Coll Cardiol (2007) 2.93
Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene. Circulation (2007) 2.88
Cardiac resynchronization therapy is more effective in women than in men: the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) trial. J Am Coll Cardiol (2011) 2.84
The assessment of endothelial function: from research into clinical practice. Circulation (2012) 2.68
Genotype-phenotype aspects of type 2 long QT syndrome. J Am Coll Cardiol (2009) 2.65
Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). Circulation (2011) 2.56
Predictors of super-response to cardiac resynchronization therapy and associated improvement in clinical outcome: the MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy) study. J Am Coll Cardiol (2012) 2.31
Left ventricular lead position and clinical outcome in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT) trial. Circulation (2011) 2.26
Platelet-derived microparticles induce angiogenesis and stimulate post-ischemic revascularization. Cardiovasc Res (2005) 2.17
Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome. JAMA (2006) 2.12
Long-term changes in serum cholesterol level does not influence the progression of coronary calcification. Int J Cardiol (2010) 1.99
Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin–Coronary Artery Disease Trial. Circulation (2011) 1.96
Reverse remodeling and the risk of ventricular tachyarrhythmias in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy). J Am Coll Cardiol (2011) 1.95
Mutations in cytoplasmic loops of the KCNQ1 channel and the risk of life-threatening events: implications for mutation-specific response to β-blocker therapy in type 1 long-QT syndrome. Circulation (2012) 1.89
Are there differences in hospital cost between patients with nosocomial methicillin-resistant Staphylococcus aureus bloodstream infection and those with methicillin-susceptible S. aureus bloodstream infection? Infect Control Hosp Epidemiol (2009) 1.86
Clinical implications for patients with long QT syndrome who experience a cardiac event during infancy. J Am Coll Cardiol (2009) 1.81
The influence of left ventricular ejection fraction on the effectiveness of cardiac resynchronization therapy: MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy). J Am Coll Cardiol (2013) 1.79
Long-term prognostic significance of left atrial volume in acute myocardial infarction. J Am Coll Cardiol (2004) 1.76
Differential role of platelet granular mediators in angiogenesis. Cardiovasc Res (2004) 1.72
The limitations of using hospital controls in cancer etiology--one more example for Berkson's bias. Eur J Epidemiol (2003) 1.72
Lipid-modifying therapies and risk of pancreatitis: a meta-analysis. JAMA (2012) 1.71
Long QT syndrome and pregnancy. J Am Coll Cardiol (2007) 1.71
Long QT Syndrome. Curr Probl Cardiol (2008) 1.70
Long-term follow-up for brain tumor development after childhood exposure to ionizing radiation for tinea capitis. Radiat Res (2005) 1.67
External counterpulsation therapy improves endothelial function in patients with refractory angina pectoris. J Am Coll Cardiol (2003) 1.63
Left atrial contractile function following a successful modified Maze procedure at surgery and the risk for subsequent thromboembolic stroke. J Am Coll Cardiol (2011) 1.62
Serum uric acid for risk stratification of patients with coronary artery disease. Cardiology (2009) 1.61
Risk factors for recurrent syncope and subsequent fatal or near-fatal events in children and adolescents with long QT syndrome. J Am Coll Cardiol (2011) 1.59
Increased platelet adhesion under flow conditions is induced by both thalassemic platelets and red blood cells. Thromb Haemost (2008) 1.59
Health services utilization in Jerusalem under terrorism. Am J Psychiatry (2006) 1.57
Dyssynchrony and the risk of ventricular arrhythmias. JACC Cardiovasc Imaging (2013) 1.56
Preauthorization of CT and MRI examinations: assessment of a managed care preauthorization program based on the ACR Appropriateness Criteria and the Royal College of Radiology guidelines. J Am Coll Radiol (2006) 1.56
Obesity as a risk factor for sustained ventricular tachyarrhythmias in MADIT II patients. J Cardiovasc Electrophysiol (2007) 1.55
Intracoronary injection of in situ forming alginate hydrogel reverses left ventricular remodeling after myocardial infarction in Swine. J Am Coll Cardiol (2009) 1.54
Mutation and gender-specific risk in type 2 long QT syndrome: implications for risk stratification for life-threatening cardiac events in patients with long QT syndrome. Heart Rhythm (2011) 1.54
In silico cardiac risk assessment in patients with long QT syndrome: type 1: clinical predictability of cardiac models. J Am Coll Cardiol (2012) 1.53
Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator. Eur Heart J (2013) 1.52
Risk factors for recurrent heart failure events in the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II). J Cardiovasc Electrophysiol (2010) 1.52
Atrioventricular delay programming and the benefit of cardiac resynchronization therapy in MADIT-CRT. Heart Rhythm (2013) 1.52
Fast track evaluation of patients with acute chest pain: experience in a large-scale chest pain unit in Israel. Isr Med Assoc J (2010) 1.51
Impact of the metabolic syndrome on the clinical outcomes of non-clinically diagnosed diabetic patients with acute coronary syndrome. Am J Cardiol (2007) 1.50
Deformation dynamics and mechanical properties of the aortic annulus by 4-dimensional computed tomography: insights into the functional anatomy of the aortic valve complex and implications for transcatheter aortic valve therapy. J Am Coll Cardiol (2012) 1.49
Importance of Knowing the Genotype and the Specific Mutation When Managing Patients with Long QT Syndrome. Circ Arrhythm Electrophysiol (2008) 1.48
Combined assessment of sex- and mutation-specific information for risk stratification in type 1 long QT syndrome. Heart Rhythm (2012) 1.47
Long-term implications of cumulative right ventricular pacing among patients with an implantable cardioverter-defibrillator. Heart Rhythm (2010) 1.47
Prognostic implications of mutation-specific QTc standard deviation in congenital long QT syndrome. Heart Rhythm (2013) 1.46
Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial. JAMA (2013) 1.45
Predictors and course of high-degree atrioventricular block after transcatheter aortic valve implantation using the CoreValve Revalving System. Am J Cardiol (2011) 1.45
Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin–Acute Coronary Syndromes Trial. Circulation (2011) 1.43
Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation (2004) 1.42
Trans-catheter aortic valve implantation for non-classical indications. Isr Med Assoc J (2013) 1.42
Vascular complications in steroid treated patients undergoing transfemoral aortic valve implantation. Catheter Cardiovasc Interv (2015) 1.42
Risk of recurrent cardiac events after onset of menopause in women with congenital long-QT syndrome types 1 and 2. Circulation (2011) 1.41
Endothelial dysfunction: a crystal ball prediction for enhanced cardiovascular risk? Isr Med Assoc J (2003) 1.41
Functional response to cardiac resynchronization therapy in patients with renal dysfunction and subsequent long-term mortality. J Cardiovasc Electrophysiol (2014) 1.41
Exercise haemodynamics may unmask the diagnosis of diastolic dysfunction among patients with pulmonary hypertension. Eur J Heart Fail (2014) 1.40
Risk of syncope in family members who are genotype-negative for a family-associated long-QT syndrome mutation. Circ Cardiovasc Genet (2011) 1.40
Combination of the Killip and TIMI classifications for early risk stratification of patients with acute ST elevation myocardial infarction. Cardiology (2011) 1.40
Timing of coronary angiography and outcome in patients with non-ST elevation acute coronary syndromes and kidney disease: real-world data from the acute coronary syndromes Israeli survey. Cardiology (2011) 1.40
Percutaneous implantation of the self-expandable CoreValve for high risk patients with severe aortic valve stenosis: early Israeli experience. Isr Med Assoc J (2010) 1.39
Predictors of high-risk angiographic findings in patients with non-ST-segment elevation acute coronary syndrome. Catheter Cardiovasc Interv (2013) 1.39
Platelets selectively enhance lymphocyte adhesion on subendothelial matrix under arterial flow conditions. Thromb Haemost (2012) 1.39
Right-to-Left shunting due to a patent foramen ovate during right ventricular infarction. Isr Med Assoc J (2010) 1.38
Superior vena cava syndrome and ovarian hyperstimulation syndrome. Isr Med Assoc J (2009) 1.38
Genotyping of patients with sporadic and radiation-associated meningiomas. Cancer Epidemiol Biomarkers Prev (2005) 1.38
Response to preventive cardiac resynchronization therapy in patients with ischaemic and nonischaemic cardiomyopathy in MADIT-CRT. Eur Heart J (2010) 1.33
Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis. Thromb Haemost (2010) 1.27
Applicability of a risk score for prediction of the long-term (8-year) benefit of the implantable cardioverter-defibrillator. J Am Coll Cardiol (2012) 1.23
Prognostic significance of fragmented QRS complex for predicting the risk of recurrent cardiac events in patients with Q-wave myocardial infarction. Am J Cardiol (2007) 1.21
Risk of thyroid cancer after childhood exposure to ionizing radiation for tinea capitis. J Clin Endocrinol Metab (2006) 1.18
Risk of mortality for ventricular arrhythmia in ambulatory LVAD patients. J Cardiovasc Electrophysiol (2011) 1.10
Predictors of long-term mortality in Multicenter Automatic Defibrillator Implantation Trial II (MADIT II) patients with implantable cardioverter-defibrillators. Heart Rhythm (2008) 1.10
Platelet-derived microparticles promote invasiveness of prostate cancer cells via upregulation of MMP-2 production. Int J Cancer (2009) 1.08
Risk of fatal arrhythmic events in long QT syndrome patients after syncope. J Am Coll Cardiol (2010) 1.06
Dyssynchrony, contractile function, and response to cardiac resynchronization therapy. Circ Heart Fail (2011) 1.05
Acute myocarditis: noninvasive evaluation with cardiac MRI and transthoracic echocardiography. AJR Am J Roentgenol (2009) 1.05
Left main coronary artery atresia: extremely rare coronary anomaly in an asymptomatic adult and an adolescent soccer player. Cardiol Rev (2003) 1.04
Relationship between left atrial appendage morphology and stroke in patients with atrial fibrillation. Heart Rhythm (2013) 1.03
Permanent occlusion of feeding arteries and draining veins in solid mouse tumors by vascular targeted photodynamic therapy (VTP) with Tookad. PLoS One (2010) 1.01
Effectiveness of the implantable cardioverter defibrillator in blacks versus whites (from MADIT-II). Am J Cardiol (2006) 1.01
Cellular phone use and risk of benign and malignant parotid gland tumors--a nationwide case-control study. Am J Epidemiol (2007) 1.01
Thrombospondin-1 mediates platelet adhesion at high shear via glycoprotein Ib (GPIb): an alternative/backup mechanism to von Willebrand factor. FASEB J (2003) 1.01
Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature. Eur Heart J (2004) 1.00
Time-dependent benefit of preventive cardiac resynchronization therapy after myocardial infarction. Eur Heart J (2010) 1.00
Smoking and risk of glioma: a meta-analysis. Cancer Causes Control (2009) 1.00